Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 16, 2022

Long-Term Survival and Toxicity After 177Lu-Octreotate Peptide Radionuclide Therapy for Neuroendocrine Tumors



Additional Info

Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy
Cancer 2022 Apr 01;[EPub Ahead of Print], KR Kennedy, JH Turner, WBG MacDonald, et al

Further Reading